Pam Simpkins has more than 25 years of experience in the biopharma industry and 6 years of experience in institutional investing. She currently serves as Managing Partner and Co-Founder of Mezzopointe, LLC, a privately-held R&D strategy consulting firm that aims to optimize the value of commercialization and/or exit for biotechs. She also serves as an FDA appointee on the Advancing Development of Pediatric Therapeutics (ADEPT 9): Diversity in Clinical Trials committee. In addition, she is a member of the advisory board for 2Flo Ventures, LLC and is an advisory committee member for Women of Color in Pharma (WOCIP), where she serves on the US regulatory policy and intelligence committee.
Ms. Simpkins is a retiree of Johnson & Johnson (J&J) where she served as Senior Director & Strategy Lead in the Office of the Chief Medical Officer, focused on M&A valuation for assets across all therapeutic areas and modalities. Over the course of her career in biopharma, which also included leadership roles at Novo Nordisk and Merck & Co., she’s contributed to >$60B in closed M&A and in-licensing deals.
Prior to biopharma, Ms. Simpkins was an institutional investor at Neuberger Berman and Prudential Investments (now PGIM). Early in her career she practiced as a CPA at Coopers & Lybrand (now PwC).
Academic Credentials
Pam holds a BS, Accounting from SUNY Albany and an MBA from Harvard Business School.
